Diversity Supplement: Targeting chemoresistant prostate cancer with novel EED inhibitors

多样性补充：用新型 EED 抑制剂靶向化疗耐药性前列腺癌

• 批准号: 10747516
• 负责人: DAQING WU
• 金额: $ 5.92万
• 依托单位: CLARK ATLANTA UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-01 至 2027-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10747516
• 关键词: African American; Biological Sciences; Chemoresistance; Clinical Pharmacology; Environment; Funding; Grant; In Vitro; Laboratory Research; Lead; Malignant neoplasm of prostate; Parents; Pharmaceutical Preparations; Pharmacology; Pharmacology and Toxicology; Pre-Clinical Model; Property; Qualifying; Research Personnel; Research Project Grants; Toxicology; Training; anticancer research; experience; graduate student; in vivo; inhibitor; novel; parent grant; programs; training project

This Diversity Supplement will train Ms. Skylar Grayson, a highly qualified African American researcher, in cancer research and prepare her for a doctoral program in biological sciences, clinical pharmacology, or toxicology. Ms. Grayson will participate in the Specific Aims 2 and 3 as outlined in the parent grant, specifically, evaluating the in vitro and in vivo activities of new EED inhibitors against chemoresistant PCa in preclinical models and determining the drug-like properties and toxicology of lead compounds. We will provide a candidate-specific training environment to maximize Ms. Grayson’s potential as a graduate student in pharmacology or toxicology.

这一多样性补充将培训斯凯拉格雷森女士，一个高素质的非洲裔美国人研究员，在 癌症研究，并准备她在生物科学，临床药理学博士课程，或 毒理学格雷森女士将参加父母补助金中概述的具体目标2和3，具体来说， 评价新的EED抑制剂在临床前对化疗耐药PCa的体外和体内活性 模型和确定药物的性质和铅化合物的毒理学。核心提供 候选人特定的培训环境，以最大限度地发挥格雷森女士作为研究生的潜力， 药理学或毒理学。

项目成果

Manipulating expression of endogenous oncogenic proteins using an antisense oligonucleotide approach in prostate cancer cells.

使用反义寡核苷酸方法在前列腺癌细胞中操纵内源性致癌蛋白的表达。

• DOI: 10.1385/1-59259-356-9:143
• 发表时间: 2003
• 期刊: Methods in molecular biology (Clifton, N.J.)
• 作者: Wu,Daqing;Wescott,GingerG;Terrian,DavidM
• 通讯作者: Terrian,DavidM